Literature DB >> 15084933

Cytokines and chronic rejection: a study in kidney transplant long-term survivors.

Mariafederica Uboldi de Capei1, Ennia Dametto, Maria E Fasano, Maria Messina, Loredana Pratico', Sabina Rendine, Giuseppe Segoloni, Emilio S Curtoni.   

Abstract

BACKGROUND: In part, the long-term survival of kidney transplants depends on the efforts to perform grafts with good human leukocyte antigen (HLA) compatibility, but there are other mechanisms that must induce some sort of tolerance and impair the anti-graft immune reaction. Because cytokines are one of the main components of immune response, we evaluated single nucleotide polymorphisms (SNPs) of several cytokine genes that may influence the production of a given cytokine and therefore the features of immune reactions.
METHODS: A total of 416 first cadaveric kidney transplants were monitored for HLA matching. After 10 years, the graft was still functional in 171 of 416 patients; 102 of 171 patients were also typed for cytokine polymorphisms.
RESULTS: The mismatch distributions in patients who underwent transplantation were not statistically different from the entire group of patients who underwent transplantation during the same time period. Moreover, it seems that almost all of the HLA class I incompatible long-term survivors are homozygous for GG at the -1082 interleukin (IL)-10 or CC at the -33IL4.
CONCLUSIONS: We observed that a match for class I and class II HLA antigens apparently does not favor the long-term survival of transplanted kidneys. In fact, matched grafts are lost before 10 years in the same proportion as the mismatched grafts. We also demonstrated (1) that patients who are homozygous for GG at the SNP -1082IL10 (high IL-10 producers) and HLA class I mismatched (but matched for class II) are protected from chronic rejection, and (2) that patients who are homozygous for CC at the SNP -33IL4 (low IL-4 producers) and HLA class I mismatched (regardless of matching for class II) are protected from chronic rejection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15084933     DOI: 10.1097/01.tp.0000114291.01231.dd

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Genetic determinants of renal transplant outcome: where do we stand?

Authors:  Paul J Phelan; Peter J Conlon; Matthew A Sparks
Journal:  J Nephrol       Date:  2014-02-11       Impact factor: 3.902

2.  Peri- and Postoperative Treatment with the Interleukin-1 Receptor Antagonist Anakinra Is Safe in Patients Undergoing Renal Transplantation: Case Series and Review of the Literature.

Authors:  Catharina M Mulders-Manders; Marije C Baas; Femke M Molenaar; Anna Simon
Journal:  Front Pharmacol       Date:  2017-05-31       Impact factor: 5.810

3.  Association of IL1 beta gene polymorphism and allograft functions in renal transplant recipients :a case control study from Kashmir Valley.

Authors:  Mohammad Ashraf Bhat; Manzoor Ahmad Parry; Saniya Nissar; Aga Syed Sameer; Imtiyaz A Bhat; Zafar A Shah; Roohi Rasool
Journal:  BMC Nephrol       Date:  2017-03-30       Impact factor: 2.388

4.  Association of pro/anti-inflammatory cytokine gene variants in renal transplant patients with allograft outcome and cyclosporine immunosuppressant levels.

Authors:  Parmeet Kaur Manchanda; Anant Kumar; Raj K Sharma; Himanshu Goel; Rama Devi Mittal
Journal:  Biologics       Date:  2008-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.